Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28. doi:10.1016/s1470-2045(09)70311-0CrossRefPubMedGoogle Scholar

Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesia R, Zhang A, Oliner KS, VanderWalde A (2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):221–232. doi:10.1016/s1470-2045(14)71200-8CrossRefPubMedGoogle Scholar

Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y (2015) Gefitinib combined with standard Chemoradiotherapy in EGFR-mutant locally advanced non-small-cell lung cancer: the LOGIK0902/OLCSG0905 intergroup study protocol. Clin Lung Cancer. doi:10.1016/j.cllc.2015.08.004PubMedGoogle Scholar

Rodel F, Frey B, Multhoff G, Gaipl U (2015) Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 356(1):105–113. doi:10.1016/j.canlet.2013.09.015CrossRefPubMedGoogle Scholar

Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, Li G, Tang W, Peng P, Zhang L (2015) The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6(16):14209–14219CrossRefPubMedPubMedCentralGoogle Scholar

Crusz SM, Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12(10):584–596. doi:10.1038/nrclinonc.2015.105CrossRefPubMedGoogle Scholar

Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M (2013) Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 13(2):241–255. doi:10.1517/14712598.2012.756469CrossRefPubMedGoogle Scholar

Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, Gewirtz DA (2005) p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol 81(6):445–458CrossRefPubMedGoogle Scholar

Lauber K, Ernst A, Orth M, Herrmann M, Belka C (2012) Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol 2:116. doi:10.3389/fonc.2012.00116CrossRefPubMedPubMedCentralGoogle Scholar